"The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency&rsq"...
- Patient Information:
Details with Side Effects
- To contact a healthcare professional for severe signs and symptoms of infusion reactions. ,
- To take premedications as prescribed [see DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS].
- To report any signs or symptoms of cytopenias (bleeding, easy bruising, petechiae or purpura, pallor, weakness or fatigue) [see WARNINGS AND PRECAUTIONS].
- To avoid medications that interfere with platelet function, except as directed by a healthcare professional [see WARNINGS AND PRECAUTIONS].
- To seek prompt medical evaluation for diffuse rash, bullae, or desquamation of the skin or oral mucosa [see WARNINGS AND PRECAUTIONS].
- To immediately report symptoms of infection (e.g. pyrexia) [see ADVERSE REACTIONS].
- That immunization with live viral vaccines is not recommended for 12 months following the Zevalin therapeutic regimen [see WARNINGS AND PRECAUTIONS].
- To use effective contraceptive methods during treatment and for a minimum of 12 months following Zevalin therapy [see WARNINGS AND PRECAUTIONS], Use in Specific Populations and Nonclinical Toxicology].
- To discontinue nursing during and after Zevalin treatment [see Use In Special Populations].
Last reviewed on RxList: 12/21/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Zevalin Information
Zevalin - User Reviews
Zevalin User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Find out what women really need.